Scarica l'app Stockscreener
4.79
5.71%
-0.29
Pre-mercato:
4.59
-0.20
-4.18%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MYGN Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$5.08
Aprire:
$5.04
Volume 24 ore:
1.20M
Relative Volume:
0.74
Capitalizzazione di mercato:
$452.38M
Reddito:
$824.50M
Utile/perdita netta:
$-365.90M
Rapporto P/E:
-1.2117
EPS:
-3.9531
Flusso di cassa netto:
$-25.60M
1 W Prestazione:
-4.20%
1M Prestazione:
+2.79%
6M Prestazione:
-40.50%
1 anno Prestazione:
-34.29%
Intervallo 1D:
$4.545
$5.065
Intervallo di 1 settimana:
$4.545
$5.31
Portata 52W:
$3.76
$8.59
Myriad Genetics Inc Stock (MYGN) Company Profile
Nome
Myriad Genetics Inc
Settore
Industria
Telefono
801-584-3600
Indirizzo
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Compare MYGN vs TMO, DHR, IDXX, A, WAT
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
4.79 | 471.27M | 824.50M | -365.90M | -25.60M | -3.9531 |
TMO
Thermo Fisher Scientific Inc
|
466.70 | 194.94B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
178.57 | 137.69B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
560.93 | 45.19B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
114.42 | 34.50B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
311.20 | 32.91B | 3.17B | 642.63M | 516.49M | 10.77 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-21 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| 2025-05-08 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-05-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-04-09 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-03-12 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-02-12 | Iniziato | Craig Hallum | Buy |
| 2024-12-10 | Iniziato | UBS | Neutral |
| 2024-12-09 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-09-19 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-08-28 | Iniziato | Wells Fargo | Overweight |
| 2024-06-27 | Iniziato | Scotiabank | Sector Outperform |
| 2024-06-03 | Ripresa | Jefferies | Underperform |
| 2024-05-08 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2023-12-21 | Ripresa | Piper Sandler | Neutral |
| 2023-12-19 | Iniziato | Wells Fargo | Equal Weight |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-07-05 | Ripresa | JP Morgan | Underweight |
| 2023-05-23 | Aggiornamento | Goldman | Sell → Buy |
| 2023-01-18 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2022-10-06 | Iniziato | Stephens | Equal-Weight |
| 2021-10-15 | Ripresa | Cowen | Market Perform |
| 2021-06-15 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-03 | Iniziato | Goldman | Sell |
| 2019-09-26 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2019-08-14 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2019-08-02 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2019-08-01 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2019-07-29 | Downgrade | Needham | Strong Buy → Hold |
| 2019-07-09 | Downgrade | Cowen | Outperform → Market Perform |
| 2019-03-12 | Reiterato | Needham | Strong Buy |
| 2019-01-03 | Iniziato | Needham | Strong Buy |
| 2018-11-30 | Aggiornamento | Goldman | Sell → Neutral |
| 2018-10-10 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2018-07-11 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-03-21 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2018-01-29 | Iniziato | Goldman | Sell |
| 2018-01-22 | Reiterato | Barclays | Equal Weight |
| 2018-01-05 | Iniziato | BTIG Research | Buy |
| 2017-10-02 | Ripresa | Leerink Partners | Mkt Perform |
| 2017-08-09 | Reiterato | Barclays | Equal Weight |
| 2017-02-08 | Aggiornamento | Ladenburg Thalmann | Sell → Neutral |
| 2017-01-18 | Iniziato | Deutsche Bank | Sell |
| 2016-10-10 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
Mostra tutto
Myriad Genetics Inc Borsa (MYGN) Ultime notizie
Forbes ranks Myriad Genetics among top U.S. employers for company culture in 2026 - Traders Union
EPO Biomarkers Market Outlook 2026-2033: Growth Drivers, - openPR.com
MYGN Stock Price, Quote & Chart | MYRIAD GENETICS INC (NASDAQ:MYGN) - ChartMill
Myriad (MYGN) up 4.1% since last earnings report: Can it continue? - MSN
Myriad Genetics (MYGN) to Present at AACR Annual Meeting 2026 - GuruFocus
Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026 - ChartMill
Myriad Genetics, Inc. (NASDAQ:MYGN) Sees Significant Decline in Short Interest - MarketBeat
Myriad Genetics (NASDAQ: MYGN) COO has 1,069 shares withheld for RSU taxes - Stock Titan
Tax withholding trims Myriad Genetics (MYGN) CSO stake by 946 shares - Stock Titan
Myriad Genetics (NASDAQ:MYGN) Stock Rating Upgraded by TD Cowen - MarketBeat
[ARS] MYRIAD GENETICS INC SEC Filing - Stock Titan
Myriad Genetics (NASDAQ: MYGN) sets 2026 votes and outlines cancer-focused growth - Stock Titan
Myriad Genetics Expands MyChoice Test Access for Prostate Cancer Patients in Japan - National Today
Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan - Bitget
GeneCentric to Present Data on Fragmentomics-Based ExpressCT™ Liquid Biopsy Technology at AACR 2026 - Yahoo Finance
Myriad Genetics jumps after Q4 beat; sees Q1 revenue rising 2%–4% Y/Y - MSN
Japan clears Myriad test for prostate cancer patients using Lynparza - Stock Titan
Sectors Review: What is the next catalyst for Myriad Genetics IncPortfolio Return Report & Low Risk High Reward Ideas - baoquankhu1.vn
Should You Hold Myriad Genetics Stock in Your Portfolio Right Now? - MSN
Lobbying Update: $30,000 of TIBER CREEK GROUP ON BEHALF OF MYRIAD GENETICS INC. lobbying was just disclosed - Quiver Quantitative
Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting - ChartMill
Aberdeen Group plc Purchases 246,748 Shares of Myriad Genetics, Inc. $MYGN - MarketBeat
Can Myriad Genetics Inc maintain its current growth rate2026 Opening Moves & Long Hold Capital Preservation Tips - baoquankhu1.vn
Trend Report: Can Myriad Genetics Inc maintain its current growth rate2026 Opening Moves & Long Hold Capital Preservation Tips - baoquankhu1.vn
Market Outlook: Whats next for Myriad Genetics Inc stockMarket Trend Report & AI Optimized Trade Strategies - baoquankhu1.vn
MYGN Technical Analysis | Trend, Signals & Chart Patterns | MYRIAD GENETICS INC (NASDAQ:MYGN) - ChartMill
Myriad Genetics, Inc. (MYGN) stock price, news, quote and history - Yahoo Finance UK
Myriad Genetics | SCHEDULE 13G/A: Others - Moomoo
BlackRock (NYSE: MYGN) holds 7.98M shares, 8.5% stake reported - Stock Titan
Myriad Genetics Q4 2025 Results: Revenue Beat, Raised GuidanceNews and Statistics - IndexBox
Myriad Genetics And 2 Other Penny Stocks To Watch Closely - Yahoo Finance
Myriad Genetics, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire
Q4 Earnings Highlights: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks - Yahoo Finance
Myriad Genetics: Market Pricing in Failure as Catalysts Build for Re-Rating - Bitget
Myriad Genetics Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Myriad Genetics Inc (MYD.HA) Stock Price, News, Quote & History - ca.finance.yahoo.com
3 Healthcare Stocks with Open Questions - Yahoo Finance
Myriad Genetics: SOTP Suggests The Company Is Undervalued - Seeking Alpha
Myriad Genetics, Inc. (MYD.F) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
Elanco, Tandem Diabetes, Fortrea, Natera, and Myriad Genetics Shares Plummet, What You Need To Know - Yahoo Finance
Vanguard (MYGN) amendment shows 0 shares; subsidiaries disaggregate holdings - Stock Titan
Myriad Genetics, Inc. (NASDAQ:MYGN) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Myriad (MYGN) Up 4.1% Since Last Earnings Report: Can It Continue? - finance.yahoo.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Myriad Genetics Inc Azioni (MYGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):